Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Oropharyngeal Cancer: early-phase trial registry
10 of 26 indexed Oropharyngeal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #627 of 28,707 conditions by registered trial count.
26 US clinical trials · 10 currently recruiting · #627 of 28,707 conditions by registered trial count
Oropharyngeal Cancer: 26 US clinical trials tracked, 10 recruiting.
Oropharyngeal Cancer is the subject of 26 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition oropharyngeal-cancer
OPEN 10 | RECR 38% | LATE 1 | EARLY 12 | RANK #627 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Oropharyngeal Cancer lists 10 open slots (38% of 26 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Oropharyngeal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Oropharyngeal Cancer recruits in line with its size-band peers.
10 of 26 indexed trials (38.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Oropharyngeal Cancer research.
M.D. Anderson Cancer Center accounts for 5 of 26 trials (19.2%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Oropharyngeal Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 26 trials that report a genuine target (sentinel values excluded). 16 of those (61.5%) plan for fewer than 100 participants.
-
Oropharyngeal Cancer splits between interventional and observational designs.
17 interventional and 9 observational studies make up this index (65.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
26 total, page 1 of 1
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Canadian Cancer Trials Group
NCT05451004
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
H. Lee Moffitt Cancer Center and Research Institute
NCT06305676
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
University of Michigan Rogel Cancer Center
NCT05894083
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Memorial Sloan Kettering Cancer Center
NCT05491512
Liposomal Bupivacaine and Transoral Robotic Surgery
Geisinger Clinic
NCT05862792
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07209189
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Zachary Zumsteg
NCT06445114
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
University of Chicago
NCT07290621
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Ryan Carey
NCT06747390
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
M.D. Anderson Cancer Center
NCT05363709
Men and Women Offering Understanding of Throat HPV
Johns Hopkins University
NCT03644563
Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial
Rutgers, The State University of New Jersey
NCT04713449
Depression and Adherence in Head and Neck Cancer
M.D. Anderson Cancer Center
NCT00498875
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
Abramson Cancer Center at Penn Medicine
NCT03729518
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
M.D. Anderson Cancer Center
NCT03224000
EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers
Sanford Health
NCT03777384
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT04708470
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Cancer Institute (NCI)
NCT04287868
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Cancer Institute (NCI)
NCT04432597
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
Memorial Sloan Kettering Cancer Center
NCT05814549
Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection
M.D. Anderson Cancer Center
NCT00508170
Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer
Mahesh Kudrimoti
NCT01084733
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Icahn School of Medicine at Mount Sinai
NCT01358097
Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study
Intuitive Surgical
NCT03049280
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
M.D. Anderson Cancer Center
NCT00490282
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
University of Texas Southwestern Medical Center
NCT04580446
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Oropharyngeal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Oropharyngeal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Oropharyngeal Cancer page
26 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Oropharyngeal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Oropharyngeal Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oropharyngeal Cancer condition card totals 26 registered trials; most-linked intervention M7824; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.